Among patients on long-term antiretroviral therapy who develop virological failure despite documented adherence, which is the most common class of resistance-associated mutations in resource-limited settings?

Explanation

## Most Common Resistance Pattern in Adherent Patients with Virological Failure **Key Point:** NNRTI resistance is the most common class of resistance-associated mutations in resource-limited settings, particularly in patients on first-line regimens containing efavirenz or rilpivirine. ### Why NNRTI Resistance Predominates #### 1. **First-Line Regimen Composition in India** The standard first-line ART regimen in India (per NACO guidelines) is: - **TDF + 3TC + EFV** (tenofovir + lamivudine + efavirenz) - Or: **TDF + 3TC + DTG** (newer, but EFV still widely used) Efavirenz is an NNRTI with a **low genetic barrier to resistance** — meaning few mutations are needed to confer high-level resistance. #### 2. **Low Genetic Barrier of NNRTIs** | Drug Class | Genetic Barrier | Mutations Needed | Clinical Relevance | |------------|-----------------|------------------|--------------------| | NNRTI | **Low** | 1–2 mutations | Rapid emergence of resistance | | NRTI | Intermediate | 2–3 mutations | Slower emergence | | PI | **High** | 4–5+ mutations | Resistant mutants less fit | | Integrase | Intermediate | 1–2 mutations | Emerging concern | **Clinical Pearl:** A single K103N mutation in reverse transcriptase confers high-level resistance to efavirenz and nevirapine — this is the most common NNRTI resistance mutation globally. #### 3. **Epidemiological Data** In India and other resource-limited settings: - NNRTI resistance: 40–60% of virological failures on first-line - NRTI resistance: 20–30% (M184V for 3TC resistance is common) - PI resistance: <5% (rarely used as first-line) - Integrase resistance: <2% (newer agents, limited exposure) ### Mechanism of NNRTI Resistance ```mermaid flowchart TD A[Patient on TDF + 3TC + EFV]:::action --> B{Virological failure despite adherence}:::decision B --> C[Subtherapeutic EFV levels or rare missed doses]:::outcome C --> D[Incomplete RT inhibition]:::outcome D --> E[Selection of K103N or Y181C mutation]:::outcome E --> F[High-level EFV resistance]:::urgent F --> G[Virological rebound]:::urgent ``` **High-Yield:** NNRTI resistance is **class-wide** — a mutation conferring resistance to efavirenz also confers resistance to nevirapine and rilpivirine. This means switching between NNRTIs is not an option; the patient must switch to a different class (PI, integrase inhibitor, or boosted PI). ### Why Other Classes Are Less Common - **NRTI resistance**: Occurs but usually alongside NNRTI mutations (dual resistance); M184V (3TC resistance) is common but does not cause virological failure alone. - **PI resistance**: Rare in first-line because PIs are not used as first-line in resource-limited settings; reserved for second-line. - **Integrase resistance**: Emerging but still rare due to limited use of integrase inhibitors in first-line regimens in India. **Mnemonic — NNRTI Low Barrier: N**evirapine, **N**on-nucleoside **R**T **I**nhibitor = **Low barrier** = Few mutations needed = **Most common resistance** in resource-limited first-line.